Brain MRI for Knee OA
Launched by TORONTO REHABILITATION INSTITUTE · Aug 3, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how our brains process pain in people with knee osteoarthritis (OA), a condition that affects millions worldwide and can cause significant discomfort and loss of mobility. Researchers will use advanced brain imaging techniques to see if certain brain areas are linked to the challenging pain experiences that many OA patients face. The goal is to gain better insights into chronic pain, which could lead to new treatment options that target the brain rather than just the knee itself.
To be eligible for this study, participants should have a confirmed diagnosis of knee OA and experience chronic pain related to this condition for at least three months. The study is looking for individuals between the ages of 65 and 74, as well as those aged 29 to 219, who can understand and speak English. Participants will undergo brain imaging and may be part of different groups based on their pain experiences. It's important to note that some health conditions or devices, like a pacemaker or joint replacement, may prevent someone from joining the study. Overall, this research aims to deepen our understanding of chronic pain and improve future treatment approaches.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Clinical diagnosis and radiographic evidence of knee OA (by rheumatologist).
- • 2. For the two experimental groups (Groups OA-Knee and OA-Knee+Body), participants must have experienced chronic pain related to their knee OA (\>3 months) on most days of each month.
- 3. Participants in Group OA-Knee+Body must:
- • Exhibit chronic knee pain and widespread bodily pain at \>3 Michigan Body Map regions.
- • Meet the Kosek criteria for nociplastic pain: i) the duration/regionality/type of pain, ii) history of hypersensitivities, iii) comorbidity identification, and iv) evoked pain hypersensitivity \[19\]
- • 4. Participants must be able to speak and understand English.
- Exclusion Criteria:
- • 1. Unable to provide consent (e.g., poor English language skills, etc.)
- • 2. History of liver or kidney disease
- 3. MRI contraindications:
- • Pacemaker
- • Stent
- • Joint prothesis
- • Implanted devices
- • Claustrophobia
- • Pregnant
- • Permanent piercings
- • 4. Chronic/abusive use of alcohol and/or illicit drugs
- • 5. Previous clinical diagnosis of fibromyalgia, a multisite pain disorder, a systemic inflammatory disorder (e.g., rheumatoid arthritis, myopathy), depression, post-traumatic stress disorder
- • 6. Previous stroke or moderate/severe traumatic brain injury, subarachnoid hemorrhage, or intracranial hemorrhage
- • 7. Use of psychotropic medications
- • 8. Control subjects (Group OA-PF) also cannot have a history of chronic pain or knee pain caused by osteoporosis or osteoarthritis
- • 9. Total knee replacement
- • 10. Pregnant or chance of being pregnant
About Toronto Rehabilitation Institute
The Toronto Rehabilitation Institute (TRI) is a leading research and clinical care organization dedicated to advancing rehabilitation science and enhancing the quality of life for individuals with disabilities and chronic health conditions. As a prominent sponsor of clinical trials, TRI focuses on innovative approaches to rehabilitation, integrating cutting-edge research with practical applications in patient care. The institute collaborates with interdisciplinary teams of experts to explore new therapies and technologies, ensuring that findings translate into effective treatments. With a commitment to improving patient outcomes, TRI is at the forefront of rehabilitation research, striving to empower individuals on their journey to recovery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Toronto, Ontario, Canada
Hamilton, Ontario, Canada
Patients applied
Trial Officials
Dinesh Kumbhare, MD, PhD
Principal Investigator
University Health Network, Toronto
Michael D Noseworthy, PhD, PEng
Principal Investigator
McMaster University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported